АГ. JournalofHypertension
 Скачать 1.94 Mb.
|
|
410. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847. 411. Rutten FH, Zuithoff NP, Halk F, Grobbee DE, Hoes AW. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:880–887. 412. Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. A co-operative study. JAMA 1977; 237:255–261. 413. Arterial hypertension. Report of a WHO expert committee. World Health Organ Tech Rep Ser 1978;7–56. 414. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428. 415. Zanchetti A. Hypertension meta-analyses: first rank evidence or second hand information? Nat Rev Cardiol 2011; 14:249–251. 416. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analysed of randomized trials. J Am Coll Cardiol 2011; 57:590–600. 417. Roush GC, Halford TR, Guddati AK. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59:1110–1117. 418. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlortalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57:689–694. 419. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709–717. 420. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al., EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11–21. 421. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-Converting Enzyme Inhibitorsand Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension 2005; 46:386–392. 422. Zanchetti A. Calcium channel blockers in hypertension. In: Black HR, Elliott WJ, editors. Hypertension, a companion to Braunwald Heart Disease. Elsevier; 2012; chapt 22:204–218. 423. Dalhof B, Sever PS, Poulter NR, Wedel H, Beevers DG, aulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindoprilas required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial. Lancet 2005;366:895–906. 424. Strauss MH, Hall AS. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin Receptor Blockers May increase risk of Myocardial Infarction: Unraveling the ARB-MI Paradox. Circulation 2006; 114:838–854. 425. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. The Lancet Oncology 2010; 11:627–636. 426. ARB Trialists collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens 2011; 29:623–635. 427. Volpe M, Azizi M, Danser AH, Nguyen G, Ruilope LM. Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur Heart J 2011; 32:19–22. 428. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111:1012–1018. 429. O’Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensinconverting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49:276–284. 430. Littlejohn TW 3rd, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25:951–959. 431. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433–2446. 432. Seed A, Gardner R, McMurray J, Hillier C, Murdoch D, Mac Fadyen R, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eurj Heart Fail 2007; 9:1120–1127. 433. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffer SM, Solomon SD. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204–2213. 434. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al., for the ASTRONAUT Investigators and Co-ordinators. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. The ASTRONAUT Randomized Trial. JAMA 2013; 309:1125–1135. 435. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure and episodic hypertension. Lancet 2010; 375:895–905. 436. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50:299–305. 437. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-Visit Blood Pressure Variability, Carotid Atherosclerosis and Cardiovascular Events in the European Lacidipine Study on Atherosclerosis. Circulation 2012; 126:569–578. 438. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on withinindividual variability in blood pressure and risk of stroke. Lancet Neurology 2010; 9:469–480. 439. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on inter-individual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375:906–915. 440. Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on inter-individual blood pressure variability: a systematic review. Stroke 2011; 42:2860–2865. 441. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens 2012; 30:1241–1251. 442. Zanchetti A. Wars, war games and dead bodies on the battlefield: variations on the theme of blood pressure variability. Stroke 2011; 42:2722–2724. 443. Mancia G, Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J Hypertens 2008; 26:164–168. 444. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ 2008; 336:1121–1123. 445. Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart j 2008; 29:2669–2680. 446. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am JMed 2009; 122:290–300. 447. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584–1590. 448. ALLHAT officers and co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997. 449. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255–3264. 450. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875–886. 451. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757–764. 452. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16:1823–1829. 453. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293:1145–1151. 454. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281–1285. 455. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353:611–616. 456. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., VALUE trial group. Outcomes inhypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022–2031. 457. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1003. 458. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al., CONVINCE Trial group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073–2082. 459. Pepine CJ, Handberg EM, Cooper-De Hoff RM, Marks RG, Kowey P, Messerli FH, et al., INVEST investigators. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805–2816. 460. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751–1756. 461. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Sylversten JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359–365. 462. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3–10. 463. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547–1559. 464. Matsui Y, Eguchi K, O’Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54:716–723. 465. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55:399–407. 466. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23:1296–1310. 467. Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double blind, randomised trial. Lancet 2009; 373:1341–1351. 468. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation 2000; 102:1139–1144. 469. Bjorklund K, Lind L, Zethelius B, Andren B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 2003; 107:1297–1302. 470. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1:1349–1354. 471. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304:405–412. 472. Sundstrom J, Neovius M, Tynelius P, Rasmussen F. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. BMJ 2011; 342:d643.473. 473. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circulation Cardiovascular quality and outcomes 2010; 3:135–142. 474. Blauwet LA, Hayes SN, McManus D, Redberg RF, Walsh MN. Low rate of sex-specific result reporting in cardiovascular trials. Mayo Clin Proc 2007; 82:166–170. 475. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive drugtreatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126:761–767. 476. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens 1997; 15:1063–1068. 477. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94:483–489. 478. Atthobari J, Gansevoort RT, Visser ST, de Jong PE, de Jong-van den Berg LT. The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate. Br J Clin Pharmacol 2007; 63:224–231. 479. Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005; 8 (Suppl 3):19–27. 480. Martinez F, Ramirez I, Perez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Healthcare 2012; 17:7–29. 481. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988; 319:267–273. 482. Dunn N, Thorogood M, Faragher B, de Caestecker L, Mac Donald TM, McCollum C, et al. Oral contraceptives and myocardial infarction: results of the MICA case- control study. BMJ 1999; 318:1579–1583. 483. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345:1787–1793. 484. Margolis KL, Adami HO, Luo J, Ye W, Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertility and Sterility 2007; 88:310–316. 485. Chakhtoura Z, Canonico M, Gompel A, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011; 96:1169–1174. 486. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284:72–78. 487. Chan WS, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, Ginsberg JS. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004; 164:741–747. 488. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90:3863–3870. 489. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011; 183:e1319–e1325. |